Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Thoracic 2Head & Neck 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 19Lung Neoplasms 14Multiple Myeloma 13Leukemia, Myeloid, Acute 12Glioma 10Wilms Tumor 9Lymphoma, Non-Hodgkin 9Breast Neoplasms 9Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Osteosarcoma 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Rhabdoid Tumor 7Hepatoblastoma 7Rhabdomyosarcoma 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Sarcoma, Ewing 5Rectal Neoplasms 5Melanoma 5

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 25130-nm albumin-bound paclitaxel 24Gemcitabine 22Magnetic Resonance Spectroscopy 21Doxorubicin 20olaparib 19Taxes 19Biopsy 19Albumin-Bound Paclitaxel 19Drug Therapy 16atezolizumab 13Nivolumab 13toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × X-Rays × 1 year × Clear all
NCT07020117 2026-04-21

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

Phase 1 Recruiting
150 enrolled
BreastHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡